{
    "organizations": [],
    "uuid": "c05f2fc863189eb00f7b6efa1d059bb1206b3b58",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-indias-strides-shasun-gets-us-fda/brief-indias-strides-shasun-gets-u-s-fda-nod-for-cyproheptadine-hydrochloride-tablets-idUSFWN1RP04V",
    "ord_in_thread": 0,
    "title": "BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cyproheptadine Hydrochloride Tablets",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12 (Reuters) - Strides Shasun Ltd:\n* GETS USFDA APPROVAL FOR CYPROHEPTADINE HYDROCHLORIDE TABLETS\n* PRODUCT WILL BE MANUFACTURED AT ORAL DOSAGE FACILITY AT BANGALORE\n* PRODUCT WILL BE MARKETED BY STRIDES PHARMA INC IN U.S MARKET\n* SAYS DRUG IS INDICATED TO RELIEVE ALLERGY SYMPTOMS Source text - bit.ly/2GUG4J2 Further company coverage:\n ",
    "published": "2018-04-12T14:29:00.000+03:00",
    "crawled": "2018-04-13T17:32:58.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "stride",
        "shasun",
        "ltd",
        "get",
        "usfda",
        "approval",
        "cyproheptadine",
        "hydrochloride",
        "tablet",
        "product",
        "manufactured",
        "oral",
        "dosage",
        "facility",
        "bangalore",
        "product",
        "marketed",
        "stride",
        "pharma",
        "inc",
        "market",
        "say",
        "drug",
        "indicated",
        "relieve",
        "allergy",
        "symptom",
        "source",
        "text",
        "company",
        "coverage"
    ]
}